CU20130135A7 - Imidazopiridazinas como inhibidores de quinasa akt - Google Patents

Imidazopiridazinas como inhibidores de quinasa akt

Info

Publication number
CU20130135A7
CU20130135A7 CU2013000135A CU20130135A CU20130135A7 CU 20130135 A7 CU20130135 A7 CU 20130135A7 CU 2013000135 A CU2013000135 A CU 2013000135A CU 20130135 A CU20130135 A CU 20130135A CU 20130135 A7 CU20130135 A7 CU 20130135A7
Authority
CU
Cuba
Prior art keywords
imidazopiridazinas
quinasa
akt inhibitors
akt
inhibitors
Prior art date
Application number
CU2013000135A
Other languages
English (en)
Other versions
CU24263B1 (es
Inventor
Lars Bärfacker
William Johnston Scott
Andrea Hägebarth
Stuart Ince
Hartmut Rehwinkel
Oliver Politz
Roland Neuhaus
Hans Briem
Ulf Bömer
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of CU20130135A7 publication Critical patent/CU20130135A7/es
Publication of CU24263B1 publication Critical patent/CU24263B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Imidazopiridazinas de fórmula (I) un proceso para su producción y el uso de las mismas.
CUP2013000135A 2011-04-07 2012-04-05 Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer CU24263B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07
PCT/EP2012/056300 WO2012136776A1 (en) 2011-04-07 2012-04-05 Imidazopyridazines as akt kinase inhibitors

Publications (2)

Publication Number Publication Date
CU20130135A7 true CU20130135A7 (es) 2014-02-28
CU24263B1 CU24263B1 (es) 2017-07-04

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2013000135A CU24263B1 (es) 2011-04-07 2012-04-05 Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer

Country Status (43)

Country Link
US (2) US9206185B2 (es)
EP (1) EP2694510B1 (es)
JP (1) JP5906303B2 (es)
KR (1) KR20140022057A (es)
CN (1) CN103596957B (es)
AP (1) AP3597A (es)
AR (1) AR087148A1 (es)
AU (1) AU2012238589B2 (es)
BR (1) BR112013025777A2 (es)
CA (1) CA2832374A1 (es)
CL (1) CL2013002878A1 (es)
CO (1) CO6862145A2 (es)
CR (1) CR20130515A (es)
CU (1) CU24263B1 (es)
CY (1) CY1117163T1 (es)
DK (1) DK2694510T3 (es)
DO (1) DOP2013000226A (es)
EA (1) EA024890B1 (es)
EC (1) ECSP13013008A (es)
ES (1) ES2558780T3 (es)
GT (1) GT201300238A (es)
HR (1) HRP20160011T1 (es)
HU (1) HUE026323T2 (es)
IL (1) IL228567A0 (es)
JO (1) JO3068B1 (es)
MA (1) MA35016B1 (es)
ME (1) ME02316B (es)
MX (1) MX336865B (es)
NI (1) NI201300105A (es)
PE (1) PE20141380A1 (es)
PH (1) PH12013502073A1 (es)
PL (1) PL2694510T3 (es)
PT (1) PT2694510E (es)
RS (1) RS54480B1 (es)
SG (1) SG193631A1 (es)
SI (1) SI2694510T1 (es)
SM (1) SMT201600001B (es)
TN (1) TN2013000400A1 (es)
TW (1) TWI535719B (es)
UA (1) UA111739C2 (es)
UY (1) UY34006A (es)
WO (1) WO2012136776A1 (es)
ZA (1) ZA201307223B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
UA105005C2 (uk) 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
DK2694510T3 (en) * 2011-04-07 2016-01-18 Bayer Ip Gmbh IMIDAZOPYRIDAZINER AS AKT kinase inhibitors
US9370517B2 (en) * 2012-01-10 2016-06-21 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as Akt kinase inhibitors
EP2802586B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
US20150328320A1 (en) * 2012-11-30 2015-11-19 Glaxosmithkline Llc Novel Pharmaceutical Composition
EP2964028A4 (en) * 2013-03-05 2017-06-07 University of Tennessee Research Foundation Compounds for treatment of cancer
WO2014158467A1 (en) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combination
EP2968343A4 (en) * 2013-03-14 2016-11-02 Epizyme Inc COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US10214545B2 (en) * 2014-01-09 2019-02-26 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
WO2018098411A1 (en) * 2016-11-28 2018-05-31 Bristol-Myers Squibb Company Gsk-3 inhibitors
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150368A0 (en) 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
ATE361297T1 (de) 2000-03-31 2007-05-15 Ortho Mcneil Pharm Inc Phenyl-substituierte imidazopyridine
JP3729343B2 (ja) 2000-04-27 2005-12-21 アステラス製薬株式会社 縮合ヘテロアリール誘導体
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2534292A1 (en) 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
DE602005026509D1 (de) 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
EP1784175A4 (en) 2004-08-23 2009-07-22 Merck & Co Inc INHIBITORS OF ACT ACTIVITY
CN101006062A (zh) 2004-08-24 2007-07-25 巴斯福股份公司 用作生产离子液体的起始化合物的咪唑甲基亚硫酸盐
AU2005316826A1 (en) 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN101263142A (zh) 2005-05-20 2008-09-10 阿雷生物药品公司 Raf抑制剂化合物及其使用方法
DK1898903T3 (da) 2005-06-10 2013-07-01 Merck Sharp & Dohme Inhibitorer af Akt-aktivitet
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
SG182187A1 (en) * 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
CL2008002398A1 (es) 2007-08-14 2009-07-31 Bayer Ip Gmbh Compuestos derivados de 6-(fenil piperidina) pirimidinas fusionadas con imidazol, triazol o pirozol, inhibidores de la via pi3k/akt; composicion farmaceutica; combinacion farmaceutica; y uso de los compuestos para el tratamiento de la neoplasia benigna y/o maligna y para el cancer.
MX2010001745A (es) * 2007-08-14 2010-03-10 Bayer Schering Pharma Ag Imidazoles fusionados para el tratamiento del cancer.
WO2009086130A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
CA2726317A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP2011522047A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
WO2010088177A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010213192A1 (en) * 2009-02-13 2011-08-04 Bayer Intellectual Property Gmbh Fused pyrimidines
US8614221B2 (en) 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
EP2473495A1 (en) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
US8975265B2 (en) 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
DK2694510T3 (en) * 2011-04-07 2016-01-18 Bayer Ip Gmbh IMIDAZOPYRIDAZINER AS AKT kinase inhibitors

Also Published As

Publication number Publication date
SI2694510T1 (sl) 2016-02-29
US9604989B2 (en) 2017-03-28
AP3597A (en) 2016-02-19
MX2013011699A (es) 2014-01-31
DOP2013000226A (es) 2013-11-15
RS54480B1 (sr) 2016-06-30
MA35016B1 (fr) 2014-04-03
ME02316B (me) 2016-06-20
CY1117163T1 (el) 2017-04-05
PT2694510E (pt) 2016-02-08
ZA201307223B (en) 2014-12-23
CO6862145A2 (es) 2014-02-10
JP5906303B2 (ja) 2016-04-20
UY34006A (es) 2012-10-31
ES2558780T3 (es) 2016-02-08
UA111739C2 (uk) 2016-06-10
JO3068B1 (ar) 2017-03-15
AR087148A1 (es) 2014-02-26
MX336865B (es) 2016-02-04
WO2012136776A1 (en) 2012-10-11
PE20141380A1 (es) 2014-10-18
PH12013502073A1 (en) 2014-01-13
SG193631A1 (en) 2013-11-29
JP2014510127A (ja) 2014-04-24
AU2012238589B2 (en) 2017-02-16
US9206185B2 (en) 2015-12-08
ECSP13013008A (es) 2013-12-31
SMT201600001B (it) 2016-02-25
EA024890B1 (ru) 2016-10-31
CA2832374A1 (en) 2012-10-11
CL2013002878A1 (es) 2014-05-02
DK2694510T3 (en) 2016-01-18
EA201301130A1 (ru) 2014-07-30
TW201245204A (en) 2012-11-16
AU2012238589A1 (en) 2013-11-07
HRP20160011T1 (hr) 2016-02-12
EP2694510B1 (en) 2015-10-14
US20140113901A1 (en) 2014-04-24
TWI535719B (zh) 2016-06-01
CN103596957B (zh) 2016-12-07
NI201300105A (es) 2014-07-14
TN2013000400A1 (en) 2015-03-30
CU24263B1 (es) 2017-07-04
PL2694510T3 (pl) 2016-03-31
CR20130515A (es) 2013-12-04
EP2694510A1 (en) 2014-02-12
HUE026323T2 (en) 2016-05-30
NZ616270A (en) 2015-09-25
AP2013007215A0 (en) 2013-10-31
IL228567A0 (en) 2013-12-31
GT201300238A (es) 2015-04-06
BR112013025777A2 (pt) 2016-12-20
CN103596957A (zh) 2014-02-19
KR20140022057A (ko) 2014-02-21
US20150368250A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
CU20130135A7 (es) Imidazopiridazinas como inhibidores de quinasa akt
UY34092A (es) Nuevos compuestos como inhibidores de jak
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34212A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34045A (es) Derivados de imidazopiridina como inhibidores de pi3k
UY34648A (es) Amidas como inhibidores de pim
UY33930A (es) Inhibidores novedosos de quinasas
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34401A (es) Métodos para el tratamiento de hcv
UY34402A (es) Métodos para el tratamiento de hcv
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
UY34108A (es) ?proceso para la fabricación de sustratos revestidos?.
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
BR112013029015A2 (pt) métodos para controlar a despolimerização de composições poliméricas
UY34604A (es) Inhibidores de oxadiazol de la producción de leucotrienos para terapia de combinación
CR20130597A (es) Isoxazolinas como agentes terapèuticos
UY34001A (es) Agentes para el control de la avispa de las agallas
BR112013023253A2 (pt) método para fabricação de um artigo absorvente
BR112015010699A2 (pt) processo para a obtenção simultânea de várias composições